Abstract
4/2007
vol. 109
Original paper
The results of wet AMD treatment by intravitreal injections – preliminary report
- Z Katedry i Kliniki Okulistyki II Wydziału Lekarskiego Akademii Medycznej w Warszawie
- Z Centrum Okulistycznego „Laser” w Warszawie
Klinika Oczna 2007, 109 (4): 389-393
Online publish date: 2007/12/20
Age-related macular degeneration (AMD) is the leading cause of irreversible, severe loss of vision in the developed countries.
Age-related macular degeneration (AMD) is the leading cause of irreversible, severe loss of vision in the developed countries.
One of the modern methods of treatment in neovascular form of AMD are repeated intravitreal injections of ranibizumab (Lucentis®). Ranibizumab is a recombinant, humanized, monoclonal antibody that neutralizes all biologically active forms of vascular
endothelial growth factor A (VEGF-A).
The aim of the study was to analyze the results of intravitreal ranibizumab injections in wet AMD patients. There were 57 patients enrolled in the study. 87% of them avoided any loss of visual acuity and 47.3% gained at least one line at visual acuity chart. Authors conclude that treatment with repeated intravitreal injections of ranibizumab is effective in neovascular form of AMD.
Age-related macular degeneration (AMD) is the leading cause of irreversible, severe loss of vision in the developed countries.
One of the modern methods of treatment in neovascular form of AMD are repeated intravitreal injections of ranibizumab (Lucentis®). Ranibizumab is a recombinant, humanized, monoclonal antibody that neutralizes all biologically active forms of vascular
endothelial growth factor A (VEGF-A).
The aim of the study was to analyze the results of intravitreal ranibizumab injections in wet AMD patients. There were 57 patients enrolled in the study. 87% of them avoided any loss of visual acuity and 47.3% gained at least one line at visual acuity chart. Authors conclude that treatment with repeated intravitreal injections of ranibizumab is effective in neovascular form of AMD.
Keywords
age-related macular degeneration, AMD, choroidal neovascularization, ranibizumab, intravitreal injection
Integrated with
